New software technology will make its insulin pumps even more effective.
News & Analysis: Tandem Diabetes Care
The growth stock cooled off a bit last month but has still managed to scorch the market with a 51% year-to-date gain.
The medical device company is cruising past everyone's expectations -- including its own.
The business reported first-quarter 2019 earnings -- and more positive news since.
Worries about what might happen with the U.S. healthcare system took a toll on the insulin-pump maker's share price.
Shares of the insulin pump maker have gained a whopping 1,490% over the last year.
Shares jumped after the company reported blowout fourth-quarter results and issued bullish guidance. Here's what investors need to know.
This insulin pump maker launched a revolutionary new treatment option for type 1 patients.
Shares tumble on a slow news day. What can explain the double-digit move?
The insulin pump maker won key support from Wall Street this morning.
Shares dropped by double digits on Monday. What's going on?